Olema Oncology names Jason O'Byrne as chief financial officer
The appointment, effective August 11, 2026, comes as the company approaches pivotal data from its OPERA-01 trial and prepares for a potential first commercial launch.
Olema Pharmaceuticals, Inc. announced on August 13, 2026 that Jason O'Byrne was appointed as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, approved by the Board of Directors on July 28, 2026 and effective as of August 11, 2026.1
O'Byrne, age 58, served as Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. from October 2024 to August 2026.1 Prior to that, he served as Chief Financial Officer of Caribou Biosciences, Inc. from 2021 to 2024.1 Earlier, he was Vice President and then Senior Vice President of Finance at Audentes Therapeutics, Inc. from 2019 to 2021, including through its acquisition by Astellas Pharma in 2020.1 He also spent 13 years at Genentech, Inc. and its parent Roche Group, holding finance leadership roles including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy.1
Under his offer letter, O'Byrne's initial annualized base salary is $545,000, with an annual performance bonus target of 45% of his base salary.1 He also received a sign-on bonus of $250,000 payable within 30 days of the effective date and $100,000 payable within 30 days of the first anniversary, subject to service-based repayment conditions.1 Subject to Board approval, the company will grant him an option to purchase 650,000 shares under its 2022 Inducement Plan, vesting 25% after one year and monthly thereafter over four years.1
Severance terms include 12 months of base salary plus target bonus, a prorated annual bonus, accelerated vesting of unvested time-based equity, and up to 12 months of COBRA reimbursement if terminated without cause or for good reason around a change in control.1
CEO Sean P. Bohen said the timing coincides with approaching pivotal data from OPERA-01 and preparation for the company's first potential commercial launch.1 Olema's pipeline includes palazestrant (OP-1250), an oral CERAN and SERD in two Phase 3 trials, and OP-3136, a KAT6 inhibitor in a Phase 1 study.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.